Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial-Reference-Cited by-同舟云学术

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

Published:2014-01-28 Issue:11 Volume:63 Page:1721-1727
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Cornillie Freddy,Hanauer Stephen B,Diamond Robert H,Wang Jianping,Tang Kezhen L,Xu Zhenhua,Rutgeerts Paul,Vermeire Séverine

Publisher

BMJ

Subject

Gastroenterology

Reference12 articles.

1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

2. Review article: loss of response to anti-TNF treatments in Crohn's disease;Ben-Horin;Aliment Pharmacol Ther,2011

3. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease;Maser;Clin Gastroenterol Hepatol,2006

4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease;Baert;N Engl J Med,2003

5. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease;Rutgeerts;Gastroenterology,2004

Cited by 334 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study;The Lancet Gastroenterology & Hepatology;2024-06

2. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

3. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05

4. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

5. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17